Theory Paper IIIDrNB Cardiology – Theory Notes

ANTI-INFLAMMATORY DRUGS IN CARDIOLOGY: CURRENT STATUS (2026)

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

ITHE INFLAMMATORY HYPOTHESIS

  • Residual Inflammatory Risk: Cardiovascular management has moved beyond lowering cholesterol alone to targeting residual inflammatory risk in patients who have reached their LDL cholesterol goals but still have elevated inflammation measured by high-sensitivity C-reactive protein (hsCRP).
  • Primary Signaling Pathway: The primary therapeutic target is the canonical inflammatory cascade involving the NLRP3 inflammasome, Interleukin-1 (IL-1beta), Interleukin-6 (IL-6), and hsCRP.
  • Mechanism of Plaque Instability: Intra-plaque inflammation causes thinning of the fibrous cap and increased proteolytic enzyme activity, leading to plaque rupture and thrombosis.

IIKEY CLINICAL TRIALS AND EVIDENCE

  • CANTOS Trial (Canakinumab):
    • Mechanism: Monoclonal antibody that directly neutralizes Interleukin-1 beta.
    • Key Finding: The first trial to prove that blocking inflammation reduces heart attacks and strokes (by 15 percent in post-MI patients with hsCRP greater than 2 mg/L) independently of cholesterol lowering.
    • Clinical Status: Not used in routine clinical practice due to high cost and an increased risk of fatal infections.
    • COLCOT and LoDoCo2 Trials (Colchicine):
    • Mechanism: Low-dose Colchicine (0.5 mg daily) inhibits tubulin polymerization and disrupts the NLRP3 inflammasome, reducing IL-1beta and IL-6 levels.
    • Key Finding: Demonstrated significant reductions in cardiovascular events in both recent myocardial infarction patients (23 percent reduction in COLCOT) and patients with stable chronic coronary disease (31 percent reduction in LoDoCo2).
    • Clinical Status: FDA-approved (0.5 mg, 2023) and recommended in secondary prevention (ESC 2024 CCS Class IIa; ACC/AHA 2023 Class IIb).
    • CLEAR SYNERGY / OASIS 9 Trial:
    • Study Focus: Evaluated low-dose Colchicine versus placebo in acute myocardial infarction patients.
    • Key Finding: Showed no significant benefit in reducing major cardiovascular events and noted a higher incidence of side effects such as diarrhea.
    • Clinical Impact: Shifted clinical practice toward selective use of Colchicine in stable chronic coronary disease rather than routine initiation during acute myocardial infarction.
    • RESCUE, ZEUS, and HERMES Trials (Ziltivekimab):
    • Mechanism: Fully human monoclonal antibody targeting the Interleukin-6 (IL-6) ligand.
    • Key Finding: The Phase 2 RESCUE Trial demonstrated profound, dose-dependent reductions in hsCRP, fibrinogen, and other inflammatory biomarkers with minimal side effects, leading to the ZEUS trial (CKD and ASCVD) and the HERMES trial (HFpEF). ZEUS missed its MACE endpoint (July 2026) and HERMES was stopped for futility (September 2026).
    • CIRT Trial (Methotrexate):
    • Key Finding: Low-dose Methotrexate (a broad systemic anti-inflammatory) failed to reduce cardiovascular events, suggesting that atheroprotection requires specific targeting of the NLRP3/IL-1beta/IL-6 pathway rather than general immunosuppression.
Clinical Trial Anti-Inflammatory Agent Molecular Target Key Clinical Outcome & Status
CANTOS Canakinumab Interleukin-1 beta Reduced MACE by 15% independent of lipid lowering; not in routine use due to cost and fatal infection risk
COLCOT & LoDoCo2 Colchicine (0.5 mg daily) Tubulin / NLRP3 inflammasome Reduced MACE by 23% (post-MI) and 31% (stable CAD); FDA-approved; ESC 2024 Class IIa
CLEAR SYNERGY (OASIS 9) Colchicine (0.5 mg daily) Tubulin / NLRP3 inflammasome No significant MACE reduction in acute MI; increased diarrhea; favors selective chronic use
CIRT Methotrexate Broad purine / DMARD pathway Failed to reduce cardiovascular events
RESCUE / ZEUS / HERMES Ziltivekimab Interleukin-6 (IL-6) ligand Dose-dependent CRP reduction in RESCUE; ZEUS missed MACE endpoint and HERMES stopped for futility (2026)

IIICURRENT CLINICAL STATUS AND DRUGS

  • Low-Dose Colchicine (0.5 mg Once Daily):
    • Clinical Role: The primary widely available and affordable oral anti-inflammatory agent for atherosclerotic cardiovascular disease.
    • Indication: Patients with stable chronic coronary disease on optimal statin therapy, particularly with residual inflammatory risk (hsCRP greater than 2.0 mg/L); note the trials did not require an elevated hsCRP.
    • Contraindications: Must be avoided in severe renal or hepatic disease and with strong CYP3A4 / P-glycoprotein inhibitors.
    • Statins (First-Line Dual Therapy):
    • Clinical Role: Beyond lowering LDL cholesterol, statins exert potent pleiotropic anti-inflammatory effects (as shown in the JUPITER Trial with Rosuvastatin) and remain the first-line therapy for lowering both lipids and hsCRP.
    • Targeted Interleukin-6 Inhibitors:
    • Clinical Role: Ziltivekimab lowered inflammatory markers but failed to improve outcomes in ZEUS and HERMES (2026), so IL-6 inhibition currently has no established role in ASCVD.

IVSUMMARY FOR EXAM SHEET

  • Target Pathway: NLRP3 Inflammasome to Interleukin-1beta to Interleukin-6 to hsCRP.
  • Primary Biomarker: High-sensitivity C-reactive protein (hsCRP greater than 2.0 mg/L identifies high residual inflammatory risk).
  • Main Trial Evidence: CANTOS (IL-1beta), COLCOT / LoDoCo2 / CLEAR SYNERGY (Colchicine), CIRT (Methotrexate failure), and RESCUE / ZEUS / HERMES (IL-6).
  • Clinical Algorithm: Optimize high-intensity statins (+ Ezetimibe/PCSK9i) first; add Colchicine 0.5 mg once daily for stable ASCVD patients with persistent inflammatory risk.

Key references

  • Ridker PM, et al. (CANTOS Trial): Antiinflammatory therapy with Canakinumab for atherosclerotic disease, New England Journal of Medicine.
  • Tardif JC, et al. (COLCOT Trial) & Nidorf SM, et al. (LoDoCo2 Trial): Low-dose Colchicine in post-myocardial infarction and chronic coronary disease.
  • CLEAR SYNERGY (OASIS 9) Investigators: Colchicine in acute myocardial infarction.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.